Continued Research into Skin Whitening, Anti-Aging, New Materials and DDS

「The Company made 1 presentation at the 98th Annual Meeting of the Japanese Society for Bacteriology, 1 at the 19th Annual Meeting of the Japanese Society of Chemical Biology, 1 at the 54th Symposium on Biomedical Polymers, 1 at the 67th Symposium on Natural Organic Compounds, 1 at the 71st Annual Meeting of the Japanese Society of Pharmacognosy, 1 at the 84th Annual Meeting of the Japanese Cancer Association, 1 at the 98th Annual Meeting of the Japanese Biochemical Society, 2 at the 48th Annual Meeting of the Molecular Biology Society of Japan, 1 at the 99th Annual Meeting of the Japanese Pharmacological Society, 1 at the 106th Annual Meeting of the Chemical Society of Japan and 3 at the 146th Annual Meeting of the Pharmaceutical Society of Japan. In relation to patents, the Company obtained a patent grant decision for a TGF-β signaling inhibitor.」

「The Company made 1 presentation at CSJ Chemistry Festa 2024, 1 at the 97th Annual Meeting of the Japanese Biochemical Society, 1 at the 47th Annual Meeting of the Molecular Biology Society of Japan, 1 at the 105th Annual Meeting of the Chemical Society of Japan and 4 at the 145th Annual Meeting of the Pharmaceutical Society of Japan. In relation to patents, the Company obtained patent grant decisions for an Nrf2 activator, an MAO inhibitor and a TGF-β signaling inhibitor.」

「The Company received a patent grant decision on 11 October 2024 for the invention of an Nrf2 activator.」

「The research results have been applied to products launched during the fiscal year, including the Ivy Attracty Series and White Stick C. The Company also conducted basic research into formulation technologies and useful compounds applicable to cosmetics, quasi-drugs and health foods, and presented the results in 1 presentation at the 72nd Annual Meeting of the Society of Polymer Science, Japan, 3 presentations at the 144th Annual Meeting of the Pharmaceutical Society of Japan and 1 paper in Colloids and Surfaces A. In relation to patents, the Company obtained a patent for an NF-κB/JAK dual inhibitor in March 2024.」

「The amount spent on the Company's R&D activities during the cumulative first-quarter period was ¥36.253 million. There were no material changes in the status of the Company's R&D activities during the cumulative first-quarter period.」

「In relation to patents, the Company obtained a patent for an osteoclast differentiation inhibitor in August 2022.」

「The amount spent on the Company's R&D activities during the cumulative third-quarter period was ¥109.864 million. There were no material changes in the status of the Company's R&D activities during the cumulative third-quarter period.」

「In relation to patents, the Company obtained a total of 4 patents: a PDK1 activator inhibitor in August 2021; a topical scalp preparation and a method for controlling active oxygen-scavenging activity and inhibition of carbonyl protein formation in November 2021; and JAK inhibitors in February and March 2022.」

「The amount spent on the Company's R&D activities during the cumulative second-quarter period was ¥93.746 million. There were no material changes in the status of the Company's R&D activities during the cumulative second-quarter period.」

「The Company discovered new useful compounds with immunosuppressive and osteoclast differentiation-inhibiting effects that could be applied to cosmetics, quasi-drugs and health foods, and elucidated their mechanisms of action. The results were presented at WCO-IOF-ESCEO 2020 (the World Congress on Osteoporosis / European Congress on Osteoporosis). In relation to patents, in January 2021 the Company obtained a patent for a topical preparation containing extracts of marjoram leaves and hop cones as useful compounds with angiogenesis-inhibiting effects.」

「The amount spent on the Company's R&D activities during the cumulative third-quarter period was ¥118.495 million. There were no material changes in the status of the Company's R&D activities during the cumulative third-quarter period.」

「The amount spent on the Company's R&D activities during the cumulative second-quarter period was ¥117.234 million. There were no material changes in the status of the Company's R&D activities during the cumulative second-quarter period.」

「The amount spent on the company's research and development activities during the cumulative first quarter was ¥61.095 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」

「In basic research, the company continued to focus on exploring new materials that form the basis of highly functional cosmetics, as it had in the previous fiscal year. In research into materials containing useful ingredients, it made 2 research presentations and filed a patent application at IFSCC Munich 2018. It also presented its research findings on microorganisms living on the skin at the Japanese Society of Antibacterial and Antifungal Agents.」

「The amount spent on the company's research and development activities during the cumulative third quarter was ¥187.614 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」

「The amount spent on the company's research and development activities during the cumulative second quarter was ¥122.059 million. There were no material changes in the status of the company's research and development activities during the cumulative second quarter.」

「The amount spent on the company's research and development activities during the cumulative first quarter was ¥72.692 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」

「In basic research, the company continued to focus on developing new materials that form the basis of highly functional cosmetics, as it had in the previous consolidated fiscal year. In research into materials containing useful ingredients, it presented its research findings and filed a patent application at IFSCC Seoul 2017. It also researched changes in skin condition resulting from different facial cleansing methods to demonstrate the importance of skincare techniques, and presented its findings at the Japanese Society of Cosmetic Dermatology.」

「The amount spent on research and development activities by the group as a whole during the cumulative third quarter was ¥205.701 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter.」

「The amount spent on research and development activities by the group as a whole during the cumulative second quarter was ¥128.599 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter.」

「The amount spent on research and development activities by the group as a whole during the cumulative first quarter was ¥64.675 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter.」

「In research into materials for anti-aging applications, the company presented its research findings at the 17th Research Association on Photoaging and the 29th IFSCC Congress, and also filed a patent application.」

「The amount spent on research and development activities by the group as a whole during the cumulative third quarter was ¥186.683 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter.」

「The amount spent on research and development activities by the group as a whole during the cumulative second quarter was ¥128.006 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter.」

「In basic research, the company focused on developing new materials that form the basis of highly functional cosmetics and conducted research. It obtained a patent (Patent No. 5719228) for a topical skin preparation for preventing aging for which it had filed an application. In research into materials for anti-aging applications, the company presented its research findings at the 136th Annual Meeting of the Pharmaceutical Society of Japan in the biological pharmacy, dermatology and sensory organs field, and also filed a patent application.」